NCT06133491View on ClinicalTrials.gov

Open Label, 6-month Study for High Frequency and Chronic Migraine,

Active, not recruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 31, 2024

Conditions
Chronic Migraine, Headache
Interventions
BIOLOGICAL

Daxibotulinumtonix A

SQ injections of 10u per site will be given over standard landmarks (18 sites) to patients who consent and are found eligible.

Trial Locations (2)

90067

The Los Angeles Headache Center, Los Angeles

06905

New England Institute for Clinical Research, Stamford

All Listed Sponsors
collaborator

The Los Angeles Headache Center

UNKNOWN

collaborator

Revance Therapeutics, Inc.

INDUSTRY

lead

Ki Health Partners. LLC

INDUSTRY